Clinical trial Recruiting at 1 site Interventional Ages 21 and up

Comparing PRESERFLO MicroShunt and trabeculectomy to lower eye pressure in open-angle glaucoma.

Official title: Preserflo MicroShunt Implantation Versus Trabeculectomy in Managing Open-Angle Glaucoma

Run by Medical University of Bialystok · NCT07496957 · Data updated 2026-11-12

This trial will test whether the PRESERFLO MicroShunt works as well as trabeculectomy to lower eye pressure in adults with open-angle glaucoma who need surgery.

More Primary Open Angle Glaucoma trials

Quick facts

Study typeInterventional
Ages21 Years and up
SexAll
Enrollment100 (estimated)
SponsorMedical University of Bialystok
Academic / other
Locations1 site (Bialystok, Polska)
StatusRecruiting
StartedMarch 1, 2026
Main results expectedDecember 1, 2027
Study endsDecember 1, 2028
Registry record updatedMarch 27, 2026
Trial IDNCT07496957 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 21 with primary open-angle, normal-tension, pigment dispersion, or pseudoexfoliative glaucoma inadequately controlled on medications, with IOP 14–28 mmHg, MD ≤ -3, and endothelial cell count ≥1000 who are planning glaucoma surgery.

Probably not a fit

Patients with closed-angle glaucoma, secondary open-angle glaucomas other than pigment dispersion or pseudoexfoliation, prior conjunctival or glaucoma-shunt surgery, aphakia or anterior chamber IOL, intraocular silicone oil, no light perception, or current corticosteroid use are unlikely to be eligible or to benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with open-angle glaucoma who require surgical lowering of intraocular pressure are randomly assigned 1:1 to receive either the PRESERFLO MicroShunt implant or a trabeculectomy with mitomycin C during a single operation. Outcomes measured over 12 months include intraocular pressure reduction at 12 months, need for glaucoma medications, additional glaucoma procedures, complications, and visual and ocular-structure preservation. Participants attend scheduled follow-up visits for eye-pressure measurements, vision testing, and safety monitoring. The trial enrolls patients with primary open-angle, normal-tension, pigment dispersion, or pseudoexfoliative glaucoma who remain uncontrolled on maximal tolerated medical therapy.

Why it matters

Potential benefit: If successful, the MicroShunt could provide similar long-term eye-pressure control with a less invasive procedure and potentially fewer complications or faster recovery than trabeculectomy.

How similar studies have gone: Previous observational studies and some randomized trials suggest the PRESERFLO MicroShunt can lower IOP and reduce medication use, but long-term head-to-head data versus trabeculectomy remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

-\>21 years of age

* An established diagnosis of: Primary open angle glaucoma, Normal tension glaucoma, Pigment dispersion glaucoma (PDG) or Pseudoexfoliative glaucoma (PEXG)
* Inadequately controlled on maximum tolerated medical therapy
* Mean Deviation (MD) \</= -3
* Intraocular pressure of 14-28 mmHg
* Endothelial Cell Count ≥1000 cells/mm2

Exclusion Criteria:

* An established diagnosis of: Closed-angle glaucoma or Secondary open-angle glaucoma (besides PDG and PEX)
* Lens status: Aphakic patients or Anterior chamber intraocular lens
* Previous procedures: Glaucoma shunt/valve/ surgery or cyclodestructive procedure, Selective laser trabeculoplasty within the past 3 months, Incisional ophthalmic surgery involving the conjunctiva within the past 3 months, Clear corneal cataract or trabecular meshwork surgery conducted within the past 6 months
* Presence of intraocular silicone oil
* No light perception vision
* Current corticosteroid use (ocular or oral)
* Conjunctival pathologies (e.g., pterygium)
* Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis)
* Vitreous present in the anterior chamber
* Active iris neovascularization or neovascularization of the iris within 6 months of the surgical date
* Unwillingness or inability to give consent, accept randomization or return for and participate in scheduled protocol visits

Where it's running

  • Medical University of Bialystok
    Bialystok, Polska, Poland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.